{"id":2985,"date":"2026-08-01T19:45:53","date_gmt":"2026-08-02T02:45:53","guid":{"rendered":"https:\/\/www.ultalabtests.com\/blog\/?p=2985"},"modified":"2026-08-07T10:24:18","modified_gmt":"2026-08-07T17:24:18","slug":"liver-function-tests","status":"publish","type":"post","link":"https:\/\/www.ultalabtests.com\/blog\/liver\/liver-function-tests\/","title":{"rendered":"Liver Function Tests: Enzymes, Bilirubin, Fibrosis Risk, and Hepatitis Testing"},"content":{"rendered":"\n

What Do Liver Function Tests Show?<\/h2>\n\n\n\n

Liver function tests<\/strong> are blood tests used to look for liver-cell injury, altered bile flow, bilirubin-processing problems, reduced protein or clotting-factor production, viral hepatitis, and risk of advanced fibrosis. Common tests include ALT<\/a>, AST<\/a>, alkaline phosphatase<\/a>, GGT<\/a>, total bilirubin<\/a> and direct bilirubin<\/a>, albumin<\/a>, total protein<\/a>, platelet count<\/a>, and\u2014when appropriate\u2014prothrombin time with INR<\/a>. FIB-4<\/a> combines age, AST<\/a>, ALT<\/a>, and platelets<\/a> to estimate the likelihood of advanced fibrosis, but it cannot diagnose fibrosis or cirrhosis. Many tests commonly called \u201cliver function tests\u201d measure injury rather than true function, and normal enzymes do not rule out MASLD, viral hepatitis, or fibrosis. Jaundice, confusion, vomiting blood, severe abdominal pain, or rapidly worsening illness requires prompt medical care.<\/p>\n\n\n\n

Part of the Ulta Lab Tests Knowledge Center<\/h2>\n\n\n\n

For a broader view of specimens, panels, screening, and monitoring, see the complete guide to lab tests and blood work<\/a>. This liver-testing guide also connects with metabolic health and GLP-1 monitoring<\/a>, diabetes and prediabetes blood tests<\/a>, vitamin and nutrient deficiency tests<\/a>, digestive health lab testing<\/a>, and infectious disease testing<\/a>.<\/p>\n\n\n\n

Key Facts About Liver Blood Tests<\/h2>\n\n\n\n
Core test or test group<\/th>Common specimen<\/th>Fasting or timing need<\/th>Primary purpose<\/th>Common use status<\/th>Major limitation<\/th><\/tr><\/thead>
Hepatic function panel<\/a><\/th>Blood (serum)<\/td>Often no fasting; panel instructions control<\/td>Reviews enzymes, bilirubin, albumin<\/a>, and protein pattern<\/td>Common or first-line<\/td>Does not identify a cause or stage fibrosis by itself<\/td><\/tr>
ALT<\/a> and AST<\/a><\/th>Blood (serum)<\/td>Recent strenuous exercise and illness matter<\/td>Looks for a hepatocellular injury pattern<\/td>Common or first-line<\/td>AST<\/a> can come from muscle or red cells; normal values do not exclude disease<\/td><\/tr>
Alkaline phosphatase<\/a> and GGT<\/a><\/th>Blood (serum)<\/td>Fasting usually not essential unless combined panel requires it<\/td>Helps assess cholestatic or bile-duct patterns and whether ALP<\/a> may be hepatic<\/td>Common or targeted<\/td>ALP<\/a> can come from bone or placenta; GGT<\/a> is nonspecific<\/td><\/tr>
Total and direct bilirubin<\/a><\/th>Blood (serum)<\/td>Protect specimen from handling issues; fasting varies by lab<\/td>Distinguishes predominantly conjugated from unconjugated bilirubin<\/a> patterns<\/td>Common or targeted<\/td>Cannot identify obstruction, hemolysis, or inherited causes alone<\/td><\/tr>
Albumin<\/a> and total protein<\/a><\/th>Blood (serum)<\/td>Usually no special timing<\/td>Provides context about protein synthesis and other systemic conditions<\/td>Common or monitoring<\/td>Low results also occur with inflammation, malnutrition, dilution, or protein loss<\/td><\/tr>
PT\/INR<\/a><\/th>Blood (citrated plasma)<\/td>Medication and specimen-collection details are critical<\/td>Assesses clotting time; may reflect reduced synthesis in selected liver contexts<\/td>Risk-based, monitoring, or acute care<\/td>Warfarin, vitamin K status, coagulation disorders, and collection errors affect results<\/td><\/tr>
CBC with platelets<\/a> or platelet count<\/a><\/th>Blood (EDTA whole blood)<\/td>Usually no fasting<\/td>Supplies platelet count<\/a> for FIB-4<\/a> and may show cytopenias<\/td>Common or monitoring<\/td>A low platelet count<\/a> has many non-liver causes<\/td><\/tr>
FIB-4 components and calculation<\/a><\/th>Blood plus age<\/td>Use stable AST<\/a>, ALT<\/a>, and platelet results<\/td>First-step estimate of advanced-fibrosis risk in appropriate adults<\/td>Risk-based or targeted<\/td>Not a diagnosis; age and non-liver influences can distort the score<\/td><\/tr>
Hepatitis B triple-panel testing<\/a> and hepatitis C antibody with reflex RNA<\/a><\/th>Blood (serum\/plasma)<\/td>Usually no fasting<\/td>Screens for HBV status and HCV exposure\/current infection using the correct sequence<\/td>Guideline-based screening or risk-based<\/td>Individual markers must be interpreted together; antibody alone may not show current infection<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

What Are Liver Function Tests?<\/h2>\n\n\n\n

The phrase liver function tests<\/em> is convenient but imprecise. A liver panel<\/a> usually measures a group of enzymes, bilirubin, and proteins. ALT<\/a> and AST<\/a> mainly provide evidence about cell injury; alkaline phosphatase<\/a> and GGT<\/a> help describe bile-flow or cholestatic patterns; bilirubin reflects production, processing, and excretion; and albumin<\/a> and PT\/INR<\/a> may provide information about synthetic function in the right context. These results are best read as a pattern rather than as isolated numbers.[1]<\/a><\/sup>[10]<\/a><\/sup><\/p>\n\n\n\n

The liver participates in glucose<\/a> and lipid metabolism, medication and hormone processing, bile production, protein synthesis, immune signaling, and detoxification. For that reason, abnormal liver-related results may connect with diabetes, obesity, alcohol exposure, infections, medications, inherited conditions, muscle injury, red-cell breakdown, or bile-duct disease. Symptoms alone are often insufficient because many liver conditions are silent until late stages. Objective testing can add useful information, but it cannot replace history, examination, imaging, elastography, or biopsy when those are needed.<\/p>\n\n\n\n

Why Liver Function and Metabolic Liver Testing Matter<\/h2>\n\n\n\n

Liver testing may be used for prevention, risk-based screening, evaluation of symptoms, medication monitoring, follow-up of a known condition, or assessment of an unexpected result. A baseline can be useful before or during selected treatments, when metabolic risk is increasing, or when a person has viral-hepatitis exposure risk. Trends may show whether an abnormality is transient, persistent, improving, or worsening.<\/p>\n\n\n\n

Laboratory testing matters most when it answers a defined question. Ordering every available marker can create incidental abnormalities, false-positive findings, anxiety, extra cost, and unnecessary follow-up. A focused sequence\u2014starting with the tests most likely to change next steps\u2014is usually more informative than a very large panel.<\/p>\n\n\n\n

What Laboratory Testing May Reveal<\/h2>\n\n\n\n
Finding or pattern<\/th>What the laboratory pattern may show<\/th>Responsible interpretation<\/th><\/tr><\/thead>
Hepatocellular pattern<\/th>ALT<\/a> and AST<\/a> rise disproportionately compared with alkaline phosphatase<\/a><\/td>May support evaluation for MASLD\/MASH, viral hepatitis, alcohol-related injury, medications or supplements, ischemia, autoimmune or inherited disease; not a diagnosis<\/td><\/tr>
Cholestatic pattern<\/th>Alkaline phosphatase<\/a> rises disproportionately; GGT<\/a> may support hepatic origin<\/td>May support evaluation for obstruction, biliary disease, medication effects, or infiltrative processes; imaging is often needed<\/td><\/tr>
Mixed pattern<\/th>Both aminotransferases and alkaline phosphatase<\/a> are meaningfully elevated<\/td>Can occur with medications, infections, alcohol-related disease, MASLD, and other conditions; requires context<\/td><\/tr>
Bilirubin pattern<\/th>Direct versus indirect predominance<\/td>May help separate conjugation\/excretion problems from hemolysis, ineffective red-cell production, or inherited unconjugated patterns<\/td><\/tr>
Synthetic-function concern<\/th>Low albumin<\/a> and\/or prolonged PT\/INR<\/a> in the appropriate setting<\/td>May suggest reduced hepatic synthesis, but nutrition, inflammation, protein loss, vitamin K status, anticoagulants, and other coagulation disorders must be considered<\/td><\/tr>
Portal-hypertension or fibrosis context<\/th>Lower platelet count<\/a> and an elevated risk score such as FIB-4<\/a><\/td>May justify secondary fibrosis assessment; does not establish portal hypertension, advanced fibrosis, or cirrhosis<\/td><\/tr>
Viral-hepatitis status<\/th>HBV marker combination or HCV antibody<\/a>\/RNA sequence<\/td>Can identify susceptibility, immunity, prior exposure, or current infection depending on the exact test combination<\/td><\/tr>
Metabolic pattern<\/th>Glucose<\/a>, A1C<\/a>, triglycerides<\/a>, lipids<\/a>, and liver markers considered together<\/td>May reveal cardiometabolic risk associated with MASLD but cannot prove liver fat, inflammation, or fibrosis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

What Laboratory Testing Cannot Reveal by Itself<\/h2>\n\n\n\n
Question<\/th>Why blood testing alone is insufficient<\/th><\/tr><\/thead>
Exact cause of an abnormal panel<\/th>Many diseases and non-liver conditions create overlapping patterns; history, repeat testing, targeted serology, imaging, or specialist evaluation may be needed<\/td><\/tr>
Amount of liver fat<\/th>Routine blood tests cannot measure liver-fat percentage; imaging methods have their own limitations<\/td><\/tr>
Presence of MASH from enzymes alone<\/th>Normal or abnormal ALT<\/a>\/AST<\/a> cannot reliably distinguish simple steatosis from steatohepatitis<\/td><\/tr>
Fibrosis stage from FIB-4<\/a> alone<\/th>FIB-4<\/a> is a risk-stratification tool; VCTE, ELF<\/a>, MRE, or biopsy may be needed<\/td><\/tr>
Bile-duct obstruction from ALP<\/a> or bilirubin alone<\/th>Ultrasound, MRCP, CT, endoscopy, or other procedures may be required<\/td><\/tr>
Medication causality<\/th>Drug-induced liver injury is a diagnosis of exclusion that depends on timing, competing causes, pattern, and clinical judgment<\/td><\/tr>
Liver cancer screening in the general population<\/th>AFP<\/a> or other tumor markers are not stand-alone population screening tests; surveillance is reserved for defined high-risk groups<\/td><\/tr>
Need for emergency care<\/th>Severe symptoms and rapid deterioration require clinical assessment, not routine self-directed testing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Depending on the clinical question, other evaluation may include a physical examination, abdominal ultrasound, CT or MRI, MRCP, vibration-controlled transient elastography, magnetic resonance elastography, endoscopy, liver biopsy, medication review, genetic counseling, or specialist assessment.[4]<\/a><\/sup><\/p>\n\n\n\n

Symptoms, Risk Factors, and Patient Scenarios<\/h2>\n\n\n\n
Symptom, risk factor, medication, or life stage<\/th>Possible explanations<\/th>Laboratory tests that may add information<\/th>Nonlaboratory evaluation that may be needed<\/th>Safety or urgency note<\/th><\/tr><\/thead>
No symptoms, but obesity, type 2 diabetes, dyslipidemia, hypertension, or central adiposity<\/th>MASLD\/MASH risk; another cause may coexist<\/td>ALT<\/a>, AST<\/a>, ALP<\/a>, bilirubin, platelets<\/a>, glucose<\/a>\/A1C<\/a>, lipids<\/a>; FIB-4<\/a> when appropriate; risk-based HBV\/HCV testing<\/td>History, examination, ultrasound or elastography may be needed<\/td>Normal enzymes do not rule out MASLD or fibrosis<\/td><\/tr>
Unexpected ALT<\/a> or AST<\/a> elevation<\/th>Transient illness, MASLD, alcohol, medication or supplement effect, viral hepatitis, muscle injury, hemolysis, ischemia, autoimmune or inherited disease<\/td>Repeat liver chemistries when appropriate; CK<\/a> or hemolysis testing if suggested; HBV\/HCV, iron<\/a>, or targeted tests based on history<\/td>Medication and exposure review; examination; imaging when persistent or significant<\/td>Marked elevation, jaundice, confusion, or systemic illness requires prompt evaluation<\/td><\/tr>
Alkaline phosphatase<\/a> elevation<\/th>Bile-duct or liver source, bone turnover, pregnancy, growth, medication effect<\/td>Repeat ALP<\/a>; GGT<\/a> or ALP isoenzyme testing<\/a> in selected cases; bilirubin<\/td>Right-upper-quadrant ultrasound is often used when hepatic source is suspected<\/td>Pain, fever, jaundice, or rapidly rising bilirubin can be urgent<\/td><\/tr>
Yellow skin or eyes, dark urine, pale stool, or itching<\/th>Conjugated hyperbilirubinemia, obstruction, acute hepatitis, hemolysis, or other disorders<\/td>Total and direct bilirubin<\/a>, AST<\/a>\/ALT<\/a>, ALP<\/a>\/GGT<\/a>, CBC<\/a>; additional tests selected clinically<\/td>Prompt examination and often imaging<\/td>Jaundice warrants timely professional assessment; confusion or bleeding is an emergency<\/td><\/tr>
Heavy or changing alcohol exposure<\/th>Alcohol-related liver injury, nutritional effects, pancreatitis, withdrawal risk, or other coexisting disease<\/td>AST<\/a>, ALT<\/a>, GGT<\/a>, bilirubin, CBC<\/a>\/platelets<\/a>, albumin<\/a>, PT\/INR<\/a> when indicated<\/td>Nonjudgmental alcohol history; assessment for withdrawal and other complications<\/td>An AST<\/a>-to-ALT<\/a> pattern is only a clue and cannot quantify alcohol use or diagnose disease<\/td><\/tr>
New prescription, OTC medicine, herbal product, bodybuilding, or weight-loss supplement<\/th>Drug- or supplement-induced liver injury; unrelated liver disease<\/td>Baseline or follow-up liver chemistries when indicated; bilirubin and PT\/INR<\/a> for concerning injury<\/td>Complete product\/timing review and clinician-directed causality assessment<\/td>Do not stop a prescribed medicine solely from an article or one result; urgent symptoms need immediate care<\/td><\/tr>
Possible viral exposure or no prior adult screening<\/th>Hepatitis B susceptibility, immunity, current or prior infection; hepatitis C exposure or current infection<\/td>HBV triple panel<\/a>; HCV antibody with reflex to HCV RNA<\/a>; HAV IgM<\/a> only when acute HAV is clinically suspected<\/td>Exposure assessment, vaccination review, counseling, and treatment linkage when positive<\/td>Reactive HCV antibody<\/a> alone does not prove current infection<\/td><\/tr>
Low albumin<\/a> or prolonged PT\/INR<\/a><\/th>Reduced synthesis, inflammation, malnutrition, protein loss, vitamin K deficiency, anticoagulant effect, coagulation disorder, or advanced illness<\/td>Repeat\/confirm as appropriate; liver chemistries, CBC<\/a>, renal and urine testing, medication review<\/td>Clinical assessment; nutrition, kidney, GI, and coagulation evaluation<\/td>Acute hepatitis with prolonged PT\/INR<\/a> or encephalopathy requires immediate specialist or emergency evaluation<\/td><\/tr>
Low platelets<\/a> with liver risk<\/th>Portal-hypertension context, splenic sequestration, immune, medication, infection, marrow, or laboratory causes<\/td>Repeat CBC<\/a>\/smear when indicated; FIB-4<\/a> only if component results are valid<\/td>Examination, imaging, hematology or hepatology assessment depending on pattern<\/td>FIB-4<\/a> may be falsely high when platelets<\/a> are low for a non-liver reason<\/td><\/tr>
Severe upper-abdominal pain, persistent vomiting, fever, or pain radiating to the back<\/th>Pancreatitis, gallbladder or bile-duct disease, infection, ischemia, or another acute condition<\/td>Clinician-selected liver tests, CBC<\/a>, lipase<\/a>, metabolic tests<\/a><\/td>Urgent examination and imaging are often more important than routine blood testing<\/td>Severe or worsening pain should not wait for direct-access test results<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Testing-Tier Overview<\/h2>\n\n\n\n

Testing tiers describe clinical role, not quality. A larger or more expensive panel is not automatically better.<\/p>\n\n\n\n

Common or First-Line Tests<\/h3>\n\n\n\n

Use status: Common or first-line.<\/strong> A hepatic function panel<\/a> or comprehensive metabolic panel<\/a> may provide ALT<\/a>, AST<\/a>, alkaline phosphatase<\/a>, bilirubin, albumin<\/a>, and related results. A CBC with platelets<\/a> adds platelet and blood-cell information. Direct bilirubin<\/a>, GGT<\/a>, or PT\/INR<\/a> may be added when the initial question or pattern calls for them.<\/p>\n\n\n\n

Risk-Based or Targeted Tests<\/h3>\n\n\n\n

Use status: Risk-based or targeted.<\/strong> Examples include the hepatitis B triple panel<\/a>; hepatitis C antibody with reflex RNA<\/a>; ferritin<\/a> and transferrin saturation<\/a>; autoimmune markers; ceruloplasmin<\/a>; alpha-1 antitrypsin<\/a>; creatine kinase<\/a> when muscle injury is plausible; and hemolysis testing for an indirect bilirubin<\/a> pattern. These tests are selected because history, age, exposure, symptoms, or a previous result creates a reason.<\/p>\n\n\n\n

Monitoring Tests<\/h3>\n\n\n\n

Use status: Monitoring.<\/strong> Repeat ALT<\/a>, AST<\/a>, ALP<\/a>, bilirubin, albumin<\/a>, PT\/INR<\/a>, CBC<\/a>\/platelets<\/a>, viral load, or treatment-specific tests may be used to follow a known condition or medication. Timing and frequency depend on the disease, therapy, baseline risk, and prior trend. Monitoring targets are not always the same as a laboratory reference interval.<\/p>\n\n\n\n

Specialist-Directed Tests<\/h3>\n\n\n\n

Use status: Specialist-directed.<\/strong> HBV DNA<\/a>, HBeAg<\/a>\/anti-HBe<\/a>, HCV RNA<\/a> for treatment, autoimmune-hepatitis workup, primary biliary cholangitis or primary sclerosing cholangitis evaluation, ELF<\/a>, elastography, MR elastography, genetic testing, and liver biopsy often require clinician selection and integrated interpretation. An isolated positive antibody or proprietary score should not be treated as a diagnosis.<\/p>\n\n\n\n

Emerging or Insufficiently Validated Tests<\/h3>\n\n\n\n

Use status: Emerging or insufficiently validated for broad self-directed use.<\/strong> Multiprotein or metabolomic panels, AI-derived imaging scores, and circulating biomarkers for MASH or fibrosis continue to evolve. Some may be useful in defined clinical pathways, but performance varies by population and disease prevalence. They should not be marketed as universal replacements for standard evaluation.<\/p>\n\n\n\n

Tests Generally Not Appropriate for Broad Routine Screening<\/h3>\n\n\n\n

Use status: Not appropriate for broad routine screening.<\/strong> Ammonia<\/a>, AFP<\/a>, CA 19-9<\/a>, broad autoimmune panels, hepatitis A IgM<\/a>, HBV DNA<\/a>, HCV RNA<\/a> without a screening or exposure reason, bile acids<\/a>, and liver biopsy are not general wellness screens. Each has a defined clinical role and a meaningful risk of confusing or incidental findings when ordered without context.<\/p>\n\n\n\n

Hepatocellular, Cholestatic, Mixed, and Bilirubin Patterns<\/h2>\n\n\n\n

Clinicians often compare each result with that laboratory\u2019s upper limit of normal rather than comparing raw values alone. The R ratio<\/strong> is an educational pattern tool: R = (ALT<\/a> \u00f7 ALT<\/a> upper limit) \u00f7 (alkaline phosphatase<\/a> \u00f7 alkaline phosphatase<\/a> upper limit)<\/strong>. It helps describe a pattern but does not diagnose a cause.[1]<\/a><\/sup><\/p>\n\n\n\n

Pattern<\/th>Typical relationship<\/th>Educational R-ratio category<\/th>Examples that may produce the pattern<\/th>Common next-step questions<\/th><\/tr><\/thead>
Hepatocellular<\/th>ALT<\/a> and AST<\/a> are elevated out of proportion to alkaline phosphatase<\/a><\/td>R ratio greater than 5<\/td>MASLD\/MASH, viral hepatitis, medications or supplements, alcohol-related injury, autoimmune hepatitis, ischemia, inherited\/metabolic disease, muscle injury mimics<\/td>Repeat\/confirm when appropriate; review exposures and symptoms; select viral, metabolic, autoimmune, muscle, and imaging evaluation based on context<\/td><\/tr>
Cholestatic<\/th>Alkaline phosphatase<\/a> is elevated out of proportion to ALT<\/a> and AST<\/a>; bilirubin may rise<\/td>R ratio less than 2<\/td>Bile-duct obstruction, gallstones, PBC, PSC, medication effects, infiltrative disease, sepsis; nonhepatic ALP<\/a> from bone or pregnancy<\/td>Confirm hepatic source with GGT<\/a> or another method; fractionate bilirubin; imaging is often needed<\/td><\/tr>
Mixed<\/th>Both ALT<\/a>\/AST<\/a> and alkaline phosphatase<\/a> are meaningfully elevated<\/td>R ratio 2 to 5<\/td>Drug or supplement injury, alcohol-associated disease, viral hepatitis, MASLD\/MASH, biliary disease, systemic illness<\/td>Use timing, symptoms, medication history, bilirubin, imaging, and targeted testing; do not infer one cause from the ratio<\/td><\/tr>
Isolated bilirubin<\/th>Bilirubin is elevated while ALT<\/a>, AST<\/a>, and ALP<\/a> are not meaningfully elevated<\/td>R ratio is not the key tool<\/td>Unconjugated: hemolysis, ineffective erythropoiesis, Gilbert syndrome; conjugated: inherited transport disorders or early hepatobiliary disease<\/td>Order total and direct bilirubin<\/a>; assess CBC<\/a>\/hemolysis context, medication history, and symptoms<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Liver Injury Markers Versus True Measures of Liver Function<\/h2>\n\n\n\n
Test<\/th>Primary role<\/th>What it may reflect<\/th>What it does not establish<\/th><\/tr><\/thead>
ALT<\/a><\/th>Liver-cell injury marker<\/td>Released with hepatocyte injury; more liver-predominant than AST<\/a><\/td>Does not measure how much liver reserve remains; normal ALT<\/a> does not rule out disease<\/td><\/tr>
AST<\/a><\/th>Injury marker with important non-liver sources<\/td>Can rise with liver injury, muscle injury, hemolysis, cardiac injury, or strenuous exercise<\/td>Cannot identify alcohol use or liver disease by itself<\/td><\/tr>
Alkaline phosphatase<\/a><\/th>Bile-flow\/cholestatic marker with non-liver sources<\/td>Can rise with hepatobiliary obstruction or cholestasis<\/td>Bone, placenta, growth, and other conditions can raise it<\/td><\/tr>
GGT<\/a><\/th>Supportive cholestatic\/enzyme-induction marker<\/td>May support a hepatic source of elevated ALP<\/a><\/td>Nonspecific; should not be used alone to screen for liver disease or alcohol use<\/td><\/tr>
Total\/direct bilirubin<\/a><\/th>Excretory-processing marker<\/td>Reflects red-cell breakdown, hepatic uptake\/conjugation, and biliary excretion<\/td>A high value does not identify the level or cause of obstruction or distinguish all inherited patterns<\/td><\/tr>
Albumin<\/a><\/th>Synthetic-function context<\/td>A major protein synthesized by the liver; persistent low values can occur with advanced disease<\/td>Long half-life and many non-liver causes make it insensitive for acute injury<\/td><\/tr>
PT\/INR<\/a><\/th>Synthetic-function and coagulation context<\/td>May lengthen when hepatic clotting-factor synthesis is impaired<\/td>Warfarin, vitamin K deficiency, DIC, factor deficiencies, and collection issues can alter it<\/td><\/tr>
Total protein\/A:G ratio<\/a><\/th>Protein-balance context<\/td>Combines albumin<\/a> and globulin fractions<\/td>Not liver-specific; immune, inflammatory, nutritional, kidney, and hematologic conditions affect it<\/td><\/tr>
Platelet count<\/a><\/th>Portal-hypertension\/fibrosis context, not a liver-function test<\/td>May fall with portal hypertension or splenic sequestration<\/td>Many immune, infectious, marrow, medication, and laboratory causes exist<\/td><\/tr>
FIB-4<\/a><\/th>Calculated fibrosis-risk estimate<\/td>Combines age, AST<\/a>, ALT<\/a>, and platelets<\/a> to help stratify advanced-fibrosis risk<\/td>Cannot diagnose or stage fibrosis; age and non-liver changes in components can mislead<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The distinction matters: a person can have very high enzymes while synthetic function remains preserved, or advanced chronic disease with enzymes that are only mildly abnormal or even within the reported reference interval.<\/p>\n\n\n\n

When Normal Enzymes Do Not Rule Out Liver Disease<\/h2>\n\n\n\n

A normal ALT<\/a> result is not proof of a normal liver. The American College of Gastroenterology notes that a normal ALT<\/a> may not exclude significant liver disease, and reference limits differ among laboratories.[1]<\/a><\/sup> Metabolic dysfunction-associated steatotic liver disease can be present with normal aminotransferases. Chronic hepatitis B or C may be asymptomatic, and fibrosis can progress without dramatic enzyme elevations.<\/p>\n\n\n\n

Risk-based questions therefore matter even when a panel is \u201cnormal\u201d:<\/p>\n\n\n\n